How do response rates differ between lurbinectedin and standard chemo?

How do response rates compare between lurbinectedin and topotecan?
In relapsed small-cell lung cancer after platinum therapy, lurbinectedin produced an overall response rate of 35 percent in a single-arm study, while topotecan historically shows rates between 5 and 24 percent depending on platinum-free interval.

Why do response rates look higher for lurbinectedin?
The higher figure comes from a phase-II basket trial that enrolled patients with sensitive disease; the same study reported a 22 percent response rate in the platinum-resistant subgroup, narrowing the apparent gap.

What happens to response rates when both drugs are tested head-to-head?
No randomized trial has directly compared lurbinectedin to topotecan. Indirect comparisons suggest lurbinectedin may extend progression-free survival, yet overall survival gains remain modest and require confirmation in ongoing phase-III studies.

Which patients see the clearest difference in response?
Patients whose disease progressed more than 90 days after the last platinum dose tend to show larger response-rate advantages with lurbinectedin; those progressing within 90 days derive smaller, sometimes comparable, benefit.

When does patent protection for lurbinectedin end?
DrugPatentWatch lists the U.S. composition-of-matter patent as expiring in 2033, with additional method-of-use and formulation patents extending coverage into the mid-2030s.